Ana I Vega1,2,3, Celia Medrano1,2,3, Rosa Navarrete1,2,3, Lourdes R Desviat1,2,3, Begoña Merinero1,2,3, Pilar Rodríguez-Pombo1,2,3, Isidro Vitoria4, Magdalena Ugarte1,2,3, Celia Pérez-Cerdá1,2,3, Belen Pérez1,2,3. 1. Centro de Diagnóstico de Enfermedades Moleculares, Centro de Biología Molecular-SO UAM-CSIC, Universidad Autónoma de Madrid, Campus de Cantoblanco, Madrid, Spain. 2. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain. 3. Instituto de Investigación La Paz (IdiPAZ), Madrid, Spain. 4. Unidad de Nutrición y Metabolopatías, Hospital La Fe, Valencia, Spain.
Abstract
PURPOSE: Glycogen storage disease (GSD) is an umbrella term for a group of genetic disorders that involve the abnormal metabolism of glycogen; to date, 23 types of GSD have been identified. The nonspecific clinical presentation of GSD and the lack of specific biomarkers mean that Sanger sequencing is now widely relied on for making a diagnosis. However, this gene-by-gene sequencing technique is both laborious and costly, which is a consequence of the number of genes to be sequenced and the large size of some genes. METHODS: This work reports the use of massive parallel sequencing to diagnose patients at our laboratory in Spain using either a customized gene panel (targeted exome sequencing) or the Illumina Clinical-Exome TruSight One Gene Panel (clinical exome sequencing (CES)). Sequence variants were matched against biochemical and clinical hallmarks. RESULTS: Pathogenic mutations were detected in 23 patients. Twenty-two mutations were recognized (mostly loss-of-function mutations), including 11 that were novel in GSD-associated genes. In addition, CES detected five patients with mutations in ALDOB, LIPA, NKX2-5, CPT2, or ANO5. Although these genes are not involved in GSD, they are associated with overlapping phenotypic characteristics such as hepatic, muscular, and cardiac dysfunction. CONCLUSIONS: These results show that next-generation sequencing, in combination with the detection of biochemical and clinical hallmarks, provides an accurate, high-throughput means of making genetic diagnoses of GSD and related diseases.Genet Med 18 10, 1037-1043.
PURPOSE: Glycogen storage disease (GSD) is an umbrella term for a group of genetic disorders that involve the abnormal metabolism of glycogen; to date, 23 types of GSD have been identified. The nonspecific clinical presentation of GSD and the lack of specific biomarkers mean that Sanger sequencing is now widely relied on for making a diagnosis. However, this gene-by-gene sequencing technique is both laborious and costly, which is a consequence of the number of genes to be sequenced and the large size of some genes. METHODS: This work reports the use of massive parallel sequencing to diagnose patients at our laboratory in Spain using either a customized gene panel (targeted exome sequencing) or the Illumina Clinical-Exome TruSight One Gene Panel (clinical exome sequencing (CES)). Sequence variants were matched against biochemical and clinical hallmarks. RESULTS: Pathogenic mutations were detected in 23 patients. Twenty-two mutations were recognized (mostly loss-of-function mutations), including 11 that were novel in GSD-associated genes. In addition, CES detected five patients with mutations in ALDOB, LIPA, NKX2-5, CPT2, or ANO5. Although these genes are not involved in GSD, they are associated with overlapping phenotypic characteristics such as hepatic, muscular, and cardiac dysfunction. CONCLUSIONS: These results show that next-generation sequencing, in combination with the detection of biochemical and clinical hallmarks, provides an accurate, high-throughput means of making genetic diagnoses of GSD and related diseases.Genet Med 18 10, 1037-1043.
Authors: Melanie A Jones; Shruti Bhide; Ephrem Chin; Bobby G Ng; Devin Rhodenizer; Victor W Zhang; Jessica J Sun; Alice Tanner; Hudson H Freeze; Madhuri R Hegde Journal: Genet Med Date: 2011-11 Impact factor: 8.822
Authors: Lindsey R Conroy; Tara R Hawkinson; Lyndsay E A Young; Matthew S Gentry; Ramon C Sun Journal: Trends Endocrinol Metab Date: 2021-10-29 Impact factor: 10.586
Authors: Laura Gieldon; Luisa Mackenroth; Anne-Karin Kahlert; Johannes R Lemke; Joseph Porrmann; Jens Schallner; Maja von der Hagen; Susanne Markus; Sabine Weidensee; Barbara Novotna; Charlotte Soerensen; Barbara Klink; Johannes Wagner; Andreas Tzschach; Arne Jahn; Franziska Kuhlee; Karl Hackmann; Evelin Schrock; Nataliya Di Donato; Andreas Rump Journal: PLoS One Date: 2018-08-09 Impact factor: 3.240
Authors: Irene Bravo-Alonso; Rosa Navarrete; Ana Isabel Vega; Pedro Ruíz-Sala; María Teresa García Silva; Elena Martín-Hernández; Pilar Quijada-Fraile; Amaya Belanger-Quintana; Sinziana Stanescu; María Bueno; Isidro Vitoria; Laura Toledo; María Luz Couce; Inmaculada García-Jiménez; Ricardo Ramos-Ruiz; Miguel Ángel Martín; Lourdes R Desviat; Magdalena Ugarte; Celia Pérez-Cerdá; Begoña Merinero; Belén Pérez; Pilar Rodríguez-Pombo Journal: J Clin Med Date: 2019-11-01 Impact factor: 4.241
Authors: Arianna Maiorana; Francesca Romana Lepri; Antonio Novelli; Carlo Dionisi-Vici Journal: Front Endocrinol (Lausanne) Date: 2022-03-29 Impact factor: 5.555